Biotech Values

[turtlepower]

These are quantifiable hard numbers, not spin.

Indeed they are. In lilly's case total non-reform costs for the quarter = 483 million

charge for the entire year for HCR = 400 million.

However lilly's PR starts off with the following

“Lilly delivered strong operational performance in the first quarter, even as we experienced continued weakness in the U.S. dollar versus prior periods and began to account for the impact from recently-enacted U.S. health care reform,” said John C. Lechleiter Ph.D., Lilly’s chairman and chief executive officer.

without mentioning the extra non-reform costs. While HRC is definitely a huge charge, lilly is clearly diverting investors attention from their other costs.